Status:
UNKNOWN
Impact of Fibroblast Growth Factor 23 (FGF-23) and Serum Phosphate on Allograft Function and Mortality in Kidney Allograft Recipients
Lead Sponsor:
Ramathibodi Hospital
Conditions:
Kidney Transplantation
Eligibility:
All Genders
18+ years
Brief Summary
The present study will examine whether serum FGF-23 and serum phosphate at baseline of kidney transplant recipients can predict progression of allograft dysfunction at 3 years and all-cause mortality ...
Eligibility Criteria
Inclusion
- at least one year post-transplantation
- no more than 10% increase in serum creatinine for the past 3 months
Exclusion
- refuse to participate in the study
- any acute illnesses
Key Trial Info
Start Date :
May 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2015
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT00903578
Start Date
May 1 2009
End Date
January 1 2015
Last Update
December 17 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ramathibodi Hospital, Mahidol University
Phayathai, Bangkok, Thailand, 10400